Overview
The study aims to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation
Eligibility
Inclusion Criteria:
- Ability to use a mobile device or computer with broadband internet access (or data streaming available)
- Ability to read, understand, and respond in English
- Adult aged 18 years of age or over at the time of the survey
- Self-confirmed diagnosis of MS
- Prescribed either OMB or OCR SC and will receive their first injection (Day 0) followed by completing the study survey between Day 1 and Day 7
Exclusion Criteria:
- Participated in an OMB or OCR randomized clinical trial
- Previously treated with OMB or OCR SC
- Cognitive impairment that impacts the patient's ability to participate in a survey study